These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33327817)

  • 41. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.
    Gao SZ; Chaparro SV; Perlroth M; Montoya JG; Miller JL; DiMiceli S; Hastie T; Oyer PE; Schroeder J
    J Heart Lung Transplant; 2003 May; 22(5):505-14. PubMed ID: 12742411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
    Steiner R; Kridel R; Giostra E; McKee T; Achermann R; Mueller N; Manuel O; Dickenmann M; Schuurmans MM; de Leval L; Fehr T; Tinguely M; Binet I; Cogliatti S; Haralamvieva E; Koller M; The Swiss Transplant Cohort Study Stcs ; Dietrich PY
    Swiss Med Wkly; 2018; 148():w14596. PubMed ID: 29518251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA; Alonso EM; Kelly SM; Rubin CM; Thistlethwaite JR; Whitington PF
    J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
    Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
    Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Post-transplant Lymphoproliferative Disorder: A Single-Center Experience.
    Ferreira H; Bustorff M; Santos J; Ferreira I; Sampaio S; Salomé I; Bastos J; Bergantim R; Príncipe F; Pestana M
    Transplant Proc; 2015 May; 47(4):981-4. PubMed ID: 26036499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
    Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
    Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience.
    Trofe J; Buell JF; Beebe TM; Hanaway MJ; First MR; Alloway RR; Gross TG; Succop P; Woodle ES
    Am J Transplant; 2005 Apr; 5(4 Pt 1):775-80. PubMed ID: 15760401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: A case report.
    Thibaud V; Rivalan J; Llamas F; Cherel M; Decaux O; Vigneau C
    Nephrol Ther; 2018 Dec; 14(7):544-547. PubMed ID: 30301610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases.
    Kremer BE; Reshef R; Misleh JG; Christie JD; Ahya VN; Blumenthal NP; Kotloff RM; Hadjiliadis D; Stadtmauer EA; Schuster SJ; Tsai DE
    J Heart Lung Transplant; 2012 Mar; 31(3):296-304. PubMed ID: 22112992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
    Kline K; Chen W; Kallen ME; Koka R; Omili D; Fan X; Iraguha T; Gebru E; Dishanthan N; Baker JM; Dietze KA; Yared JA; Hankey K; Dahiya S; Niederhaus SV; Dunleavy K; Hardy NM; Luetkens T; Rapoport AP; Atanackovic D
    Hum Vaccin Immunother; 2023 Aug; 19(2):2216116. PubMed ID: 37278257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA; Hamilton-Dutoit S; Bendtzen K
    Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kidney allograft with a lymphocytic infiltrate: acute rejection, posttransplantation lymphoproliferative disorder, neither, or both entities?
    Trpkov K; Marcussen N; Rayner D; Lam G; Solez K
    Am J Kidney Dis; 1997 Sep; 30(3):449-54. PubMed ID: 9292579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience.
    Guerra-García P; Bomken S; Ling R; Lazareva A; Gupte G; Amrolia P; Andrés M; Diez-Sebastián J; Taj MM
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31053. PubMed ID: 38757407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eosinophilic esophagitis in children following cardiac transplantation: association with post-transplant lymphoproliferative disorder and other transplant outcomes.
    Kindel SJ; Joy BF; Pahl E; Wald EL
    Pediatr Transplant; 2014 Aug; 18(5):491-6. PubMed ID: 24931365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
    Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of post-transplant lymphoproliferative disorders.
    Llaurador G; McLaughlin L; Wistinghausen B
    Curr Opin Pediatr; 2017 Feb; 29(1):34-40. PubMed ID: 27906865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.
    Kanzelmeyer NK; Maecker-Kolhoff B; Zierhut H; Lerch C; Verboom M; Haffner D; Pape L
    Transpl Int; 2018 Apr; 31(4):367-376. PubMed ID: 28906028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.